An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
NCT ID: NCT03514641
Last Updated: 2021-09-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
673 participants
INTERVENTIONAL
2017-10-18
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients
NCT02563405
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
NCT00646841
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
NCT01373086
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
NCT03640221
The Precision Hypertension Care Study
NCT02774460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
603A was a multicenter double-blind parallel group placebo-controlled study conducted to determine the placebo-adjusted change from baseline to week 12 in the mean ambulatory systolic blood pressure (SBP) of approximately 680 subjects considered generally representative of the adult hypertensive population in the United States. Secondary endpoints included the placebo-adjusted change from baseline to week 12 of the mean office seated systolic blood pressure, the change to week 12 of the mean ambulatory and mean office seated diastolic blood pressure, the proportion of subjects achieving prespecified goals for absolute systolic and diastolic blood pressure as well as prespecified goals for reduction in systolic and diastolic blood pressure, measured by ambulatory and seated office measurement methodology.
A603B was a multicenter double-blind parallel group placebo-controlled randomized withdrawal study conducted to determine the durability of the antihypertensive effect of bexagliflozin tablets, 20 mg, in a population not pre-selected for existing diabetes. All subjects entered a 12 week run-in period during which they self-administered open label bexagliflozin tablets, 20 mg once daily. At week 12 a baseline ambulatory blood pressure monitoring (ABPM) measurement was made, and the subjects were randomized one to one to receive either bexagliflozin tablets, 20 mg or bexagliflozin tablets, placebo. After a 12 week treatment period a second ABPM measurement was made. The primary endpoint was the intergroup difference in the change from baseline in the mean SBP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The primary endpoint of study 603B is the change from week 12 (cumulative week 24) to week 24 (cumulative week 36) in the 24-hour average SBP in the bexagliflozin group compared to the placebo group using a superiority testing at an overall two-sided 0.05 level of significance.
TREATMENT
QUADRUPLE
* Study 603B week 1 to week 12: bexagliflozin tablets, 20 mg, open-labeled
* Study 603B week 13 to week 24: bexagliflozin tablets, 20 mg or placebo
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
Bexagliflozin
Bexagliflozin tablet, 20 mg
Placebo
Placebo (inactive) tablet to match the active drug
Sequence 2
Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
Bexagliflozin
Bexagliflozin tablet, 20 mg
Placebo
Placebo (inactive) tablet to match the active drug
Sequence 3
Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
Bexagliflozin
Bexagliflozin tablet, 20 mg
Sequence 4
Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
Bexagliflozin
Bexagliflozin tablet, 20 mg
Placebo
Placebo (inactive) tablet to match the active drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bexagliflozin
Bexagliflozin tablet, 20 mg
Placebo
Placebo (inactive) tablet to match the active drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with essential hypertension and exhibiting an office seated SBP ≥ 140 and \< 180 mm Hg
* Unmedicated or prescribed no more than 4 agents for hypertension. Unmedicated subjects were subjects who had never taken medications for hypertension or had not taken any anti-hypertensive medication for at least 3 months. A stable dose meant no change in dose or frequency had taken place in the 4 weeks prior to the screening visit
* If female and of childbearing potential, willing to use an adequate method of contraception and to not become pregnant for the duration of the study.
* Willing and able to return for all clinic visits and to complete all study-required procedures
* Able to self-medicate during the run-in period, omitting no more than one day of dosing
* Shown to have a seated SBP ≥ 140 and \< 180 mm Hg
* Shown to exhibit a mean 24 h SBP ≥ 135 mm Hg
Prospective participants exhibiting any of the following characteristics were to be excluded from the study:
* Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young (MODY)
* Known history of secondary or malignant hypertension
* Seated diastolic blood pressure (DBP) \>110 mm Hg at screening
* Taking insulin for diabetes
* Prescribed more than 4 anti-hypertension medications
* Having a genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
* Having cancer, active or in remission for \< 3 years
* History of alcohol or illicit drug abuse in the past 2 years
* History of myocardial infarction, stroke or hospitalization for heart failure in the prior 6 months
* Previous exposure to bexagliflozin or EGT0001474
* History of hypertensive emergency
* History of sodium glucose linked transporter 2 (SGLT2) inhibitor treatment in the last 3 months
* Known intolerance or allergy to SGTL2 inhibitors
* Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
* Pregnancy or nursing
* Current participation in another interventional trial or having been exposed to an investigational drug within 30 days or 7 half-lives of screening, whichever is longer
* Arm circumference too large or small to allow accurate ambulatory monitoring
* History of kidney transplant
* Occupational or other lifestyle factors that could hamper the collection of valid ABPM data
* Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase \> 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.5 × ULN
* Estimated glomerular filtration rate (eGFR), as calculated by the modification of diet in renal disease study equation (MDRD), \< 45 mL/min/1.73 m2 or requiring dialysis
* HbA1c \> 9.5%
* Positive urine pregnancy test for female subjects of child bearing potential
* Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase \> 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.5 × ULN
* eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), \< 45 mL/min/1.73 m2 or requiring dialysis
* HbA1c \> 9.5%
* Positive urine pregnancy test for female subjects of child bearing potential
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Theracos
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Allegretti, M.D.
Role: STUDY_DIRECTOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Site
Birmingham, Alabama, United States
Clinical Research Site
Birmingham, Alabama, United States
Clinical Research Site
Birmingham, Alabama, United States
Clinical Research Site
Foley, Alabama, United States
Clinical Research Site
Gulf Shores, Alabama, United States
Clinical Research Site
Glendale, Arizona, United States
Clinical Research Site
Mesa, Arizona, United States
Clinical Research Site
Phoenix, Arizona, United States
Clinical Research Site
Tucson, Arizona, United States
Clinical Research Site
Anaheim, California, United States
Clinical Research Site
Bellflower, California, United States
Clinical Research Site
Fair Oaks, California, United States
Clinical Research Site
Fresno, California, United States
Clinical Research Site
Lincoln, California, United States
Clinical Research Site
Los Angeles, California, United States
Clinical Research Site
San Gabriel, California, United States
Clinical Research Site
Santa Rosa, California, United States
Clinical Research Site
Upland, California, United States
Clinical Research Site
Colorado Springs, Colorado, United States
Clinical Research Site
Colorado Springs, Colorado, United States
Clinical Research Site
Denver, Colorado, United States
Clinical Research Site
Golden, Colorado, United States
Clinical Research Site
Stamford, Connecticut, United States
Clinical Research Site
Decatur, Georgia, United States
Clinical Research Site
Decatur, Georgia, United States
Clinical Research Site
Lithonia, Georgia, United States
Clinical Research Site
Chicago, Illinois, United States
Clinical Research Site
Chicago, Illinois, United States
Clinical Research Site
Chicago, Illinois, United States
Clinical Research Site
Avon, Indiana, United States
Clinical Research Site
Evansville, Indiana, United States
Clinical Research Site
Indianapolis, Indiana, United States
Clinical Research Site
Council Bluffs, Iowa, United States
Clinical Research Site
Prairie Village, Kansas, United States
Clinical Research Site
Lexington, Kentucky, United States
Clinical Research Site
Paducah, Kentucky, United States
Clinical Research Site
Versailles, Kentucky, United States
Clinical Research Site
New Orleans, Louisiana, United States
Clinical Research Site
Auburn, Maine, United States
Clinical Research Site
Silver Spring, Maryland, United States
Clinical Research Site
Edina, Minnesota, United States
Clinical Research Site
Bridgeton, Missouri, United States
Clinical Research Site
St Louis, Missouri, United States
Clinical Research Site
Henderson, Nevada, United States
Clinical Research Site
Las Vegas, Nevada, United States
Clinical Research Site
Trenton, New Jersey, United States
Clinical Research Site
Albuquerque, New Mexico, United States
Clinical Research Site
Brooklyn, New York, United States
Clinical Research Site
Hartsdale, New York, United States
Clinical Research Site
The Bronx, New York, United States
Clinical Research Site
Shelby, North Carolina, United States
Clinical Research Site
Akron, Ohio, United States
Clinical Research Site
Cincinnati, Ohio, United States
Clinical Research Site
Cincinnati, Ohio, United States
Clinical Research Site
Columbus, Ohio, United States
Clinical Research Site
Dayton, Ohio, United States
Clinical Research Site
Dublin, Ohio, United States
Clinical Research Site
Grove City, Ohio, United States
Clinical Research Site
Lyndhurst, Ohio, United States
Clinical Research Site
Edmond, Oklahoma, United States
Clinical Research Site
Oklahoma City, Oklahoma, United States
Clinical Research Site
Portland, Oregon, United States
Clinical Research Site
Altoona, Pennsylvania, United States
Clinical Research Site
Hatboro, Pennsylvania, United States
Clinical Research Site
Lincoln, Rhode Island, United States
Clinical Research Site 2
Anderson, South Carolina, United States
Clinical Research Site
Anderson, South Carolina, United States
Clinical Research Site
Greer, South Carolina, United States
Clinical Research Site
Kingsport, Tennessee, United States
Clinical Research Site
Knoxville, Tennessee, United States
Clinical Research Site
Arlington, Texas, United States
Clinical Research Site
Dallas, Texas, United States
Clinical Research Site
Houston, Texas, United States
Clinical Research Site
Kingwood, Texas, United States
Clinical Research Site
Mesquite, Texas, United States
Clinical Research Site
Plano, Texas, United States
Clinical Research Site
San Antonio, Texas, United States
Clinical Research Site
Tomball, Texas, United States
Clinical Research Site
Layton, Utah, United States
Clinical Research Site
Murray, Utah, United States
Clinical Research Site
West Jordan, Utah, United States
Clinical Research Site
Arlington, Virginia, United States
Clinical Research Site
Burke, Virginia, United States
Clinical Research Site
Charlottesville, Virginia, United States
Clinical Research Site
Danville, Virginia, United States
Clinical Research Site
Manassas, Virginia, United States
Clinical Research Site
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THR-1442-C-603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.